



BlueCross BlueShield of South Carolina and BlueChoice HealthPlan of South Carolina

Independent licensees of the Blue Cross and Blue Shield Association

Note! Contents are subject to change and are not a guarantee of payment.



Agenda

- Introduction
- Services and Treatments
- Authorization Process
- Notification of Determination
- Clinical Information
- Other Important Information
- Provider Tools
- Provider Relations Contact Information



On January 1, 2015, BlueCross BlueShield of South Carolina and BlueChoice HealthPlan launched a Radiation Oncology Utilization Management Program. We selected NIA Magellan to provide these radiation oncology benefit management services through its Radiation Oncology Solution program. NIA Magellan is an independent company that provides utilization management services on behalf of BlueCross and BlueChoice[®].

Physicians designed NIA Magellan's Radiation Oncology Solution, for physicians, to ensure that services within the radiation therapy treatment plan are clinically appropriate for each patient's specific condition. It is consistent with nationally recognized clinical guidelines and ensures treatments are conducted in the most efficient and outcome-oriented manner.

Introduction



Radiation Therapy Management

BlueCross and BlueChoice are expanding the existing partnership with NIA Magellan for radiation oncology which:

- Complements NIA Magellan's expertise in diagnostic imaging management.
- Incorporates oncology diagnostic imaging and therapeutic radiology into the utilization management process.
- Will use NIA Magellan systems, tools and infrastructure to deliver the radiation oncology capability.



Introduction



Participating Plans

BlueCross and BlueChoice plans:

- 1. Fully insured
- 2. BlueCross Exchange plans
- 3. BlueChoice Exchange plans
- 4. BlueChoice commercial plans

BlueCross and BlueChoice plans **not** participating with the program include:

- 1. Federal Employees Program (FEP)
- 2. State Health Plan
- 3. Self-funded plans
- 4. Out-of-state members (BlueCard®)





- Introduction
- Services and Treatments
- Authorization Process
- Notification of Determination
- Clinical Information
- Other Important Information
- Provider Tools
- Provider Relations Contact Information



Services and Treatments



• All radiation therapy treatment

Excludes

- Hospital inpatient
- Observation
- Emergency room
- Surgery center



Services and Treatments

Program includes management of all radiation therapy modalities:

- Low-dose-rate (LDR) Brachytherapy
- High-dose-rate (HDR) Brachytherapy
- Two-dimensional Conventional Radiation Therapy (2D)
- Three-dimensional Conformal Radiation Therapy (3D-CRT)
- Intensity Modulated Radiation Therapy (IMRT)
- Image Guided Radiation Therapy (IGRT)
- Stereotactic Radiosurgery (SRS)
- Stereotactic Body Radiation Therapy (SBRT)
- Proton Beam Radiation Therapy (PBT)
- Intra-Operative Radiation Therapy (IORT)
- Neutron Beam Therapy
- Hyperthermia



Services and Treatment

- Review the Radiation
 Oncology Utilization Review
 Matrix to determine procedures
 NIA Magellan manages. Find
 procedures and their allowable
 billed groupings on
 www.RadMD.com,
 www.SouthCarolinaBlues.com
 and www.BlueChoiceSC.com.
- Defer to health plan policies for procedures we didn't list in the matrix.



BlueCross BlueShield of South Carolina and BlueChoice HealthPlan of South Carolina

Independent licensees of the Blue Cross and Blue Shield Association

Radiation Oncology Utilization Review Matrix 2015

NIA has developed this matrix in an effort to help its clients set up their claim processing systems. NIA is an independent company that provides utilization management services on behalf of BlueCross BlueShield of South Carolina and BlueChoice HealthPlan.

NIA designed this matrix to assist in the resolutions of claims adjudication and claims questions related to radiation oncology services. The matrix contains the CPT-4 codes NIA manages for the Radiation Oncology program. The codes are set up using what you would see on a professional HCFA 1500 claim. The inclusion of a code doesn't imply that we will approve the service, only that if we received a request for that service, NIA would manage it.

The "Allowable Billed Groupings" indicates that if NIA authorizes a given procedure, that you could submit any of the listed procedures codes on a claim representing that service. This assumes that you perform the service within the validity period. If an allowable billed grouping of CPT codes is not listed in this matrix, an exact match is required between the authorized CPT code and the billed CPT code. If the exact match does not occur, the charge should be adjudicated accordingly.

NIA did not list codes representing contrast agents, radiopharmaceuticals and supplies on this matrix. This table also does not include facilities using CMS Outpatient PPS logic (C codes) that submit codes.

Please note: NIA will not manage radiation services initiated while the patient is in a hospital inpatient setting, emergency room or observation room.





- Introduction
- Services and Treatments
- Authorization Process
- Notification of Determination
- Clinical Information
- Other Important Information
- Provider Tools
- Provider Relations Contact Information




Radiation Oncologist

- Determining the treatment plan
- Submitting the request for prior authorization
- Providing radiation therapy

Radiation Oncologist and Cancer Treatment Facility Ensures the receipt of prior authorization prior to providing services.







* NIA Magellan makes determinations within two days for general requests, 24 hours for urgent requests.



Step 1: Gather necessary patient and therapy information

GENERAL	 Name and office phone number of radiation oncologist planning and delivering radiation therapy Member name and ID number Name of treatment facility performing the procedures Anticipated treatment start date
CLINICAL INFORMATION	 Disease site being treated Stage (T, N, M stage) Treatment intent
TECHNIQUE Requested radiation therapy modality (initial and/or boost stages)	 Ports/angles Total dose Fractions IGRT type Brachytherapy insertions and fractions

NIA Magellan may need additional information depending on the cancer site and treatment modality. ¹³



Step 1: Gather necessary patient and therapy information

Cancer Site Checklist Example

Refer to the treatment plan checklists to determine what information we need. Checklists are specific to the type of cancer being treated and can assist in documenting clinical information and the treatment plan.




Prostate Radiation Therapy Treatment Plan Checklist -Sample

General Information					
Patient Name : Radiation Therapy Treatment Planning Start Date (i.e. Clinical Treatment Plan, Set up Simulation):// Radiation Therapy Treatment Start Date ://					
	Patient Clini	cal Information			
<u>T Stage:</u> TX T0 T1 T1a T1b T1c T2 T2a T2b T2c T3 T3a T3b T4	N Stage: NX NX N0 N1 Does patient have distant metastasis (M1)? Yes No Treatment Intent Primary Therapy Adjuvant – Post-Operation Palliative	or more tests? Yes No Highest Gleason Score: ADT (Androgen Deprivation Therapy: Not using ADT Short-term (4-6 months) Clong-term (2vrs)			
	Treatment Plar	ning Information			
1. Initial Treatment Phase (Cho	ose One) :				
2-Dimension Radiation The	rapy	3D Conformal Radiation Therapy			



Step 2: Submit necessary information



Submit authorization requests as soon as possible, following the set up simulation, to avoid delay in claims processing.



Step 2: Submit necessary information

How to Submit Authorization Requests

Initiate requests using www.RadMD.com, the preferred method:

- 1. Identify patient, physician and treatment facility
- 2. Outline the treatment plan
- 3. Complete the cancer site checklist
- 4. Describe the reason for treatment
- 5. Answer clinical questions
- 6. Confirm the information
- 7. Submit the request

Submit authorization requests as soon as possible, following the set up simulation, to avoid delay in claims processing.



Step 3: Treatment plan review

	•	
 · · · -		

National Imaging Associates, Inc.	
Clinical guidelines:	Original Date: March 2011
COLORECTAL CANCER	Page 1 of 7
Radiation Oncology	Last Review Date: October 2014
Guideline Number: NIA_CG_121	Last Revised Date: June 2012
Responsible Department:	Implementation Date : October 2014
Clinical Operations	

INTRODUCTION:

Colorectal cancer, also called colon cancer or large bowel cancer includes cancerous growths in the colon, rectum and appendix. With nearly 700,000 deaths worldwide per year, it is the fifth most common form of cancer in the United States and the third leading cause of cancer-related death in the Western world.

Invasive cancers that are confined within the wall of the colon (TNM stages I and II) are curable with surgery. If untreated, they spread to regional lymph nodes (stage III), where up to 73% are curable by surgery and chemotherapy. Cancer that metastasizes to distant sites (stage IV) is usually not curable, although chemotherapy can extend survival, and in rare cases, surgery and chemotherapy together have seen patients through to a cure.

Colorectal cancer frequently presents with no symptoms. A genetic model of carcinogenesis has been developed, starting with adenomatous polyps that progress in a stepwise process to malignancy. Screening tests can detect colorectal polyps, some of which have the potential to become cancerous. Colonoscopy, an endoscopic examination of the entire colon, allows polyp detection and enables biopsy or the removal of the polyps during the procedure. Colorectal cancer diagnosis is established by histopathological examination of the tissue obtained from biopsy of the tumor.

The method of treatment for colorectal cancer depends on whether the cancer is in the colon or the rectum and on the stage of the disease. Staging occurs after colorectal cancer has been diagnosed and it evaluates the disease location and extent. Treatment may include surgery, chemotherapy, radiation therapy, or biological therapy; it may also include some combination of these treatments. Cancers of the colon are generally treated with surgery and chemotherapy. Patients whose cancer has spread beyond the colon to other parts of the body may be given palliative radiation therapy to control symptoms of metastatic disease. Cancers of the rectum are more prone to loco-regional recurrence, and radiation therapy and chemotherapy are given either before, during or after surgery.

GOAL OF THE GUIDELINE:

This guideline outlines several methods suitable for the employment of radiation therapy in conjunction with colon and rectal cancer treatment. These include the use of external radiation (three-dimensional conformal radiation therapy (3D-CRT), intra-operative radiation treatment (IORT), and rarely, internal radiation (brachytherapy). Advanced approaches such as intensity modulated radiation therapy (IMRT) and/or image guided radiation therapy (IGRT) are not indicated as standard treatment for colorectal cancer. The

Proprietary

1-Colorectal Cancer

NIA Magellan.

Evidence-Based Clinical Guidelines for Radiation Oncology

- Nurses will review all services that are part of the treatment plan to determine appropriateness and medical necessity.
- Nurses review medical necessity based on nationally recognized, evidence-based clinical guidelines and standards of care.



Step 3: Treatment plan review

National Imaging Associates, Inc.	
Clinical guidelines:	Original Date: March 2011
COLORECTAL CANCER	Page 1 of 7
Radiation Oncology	Last Review Date: October 2014
Guideline Number: NIA_CG_121	Last Revised Date: June 2012
Responsible Department:	Implementation Date : October 2014
Clinical Operations	-

INTRODUCTION:

Colorectal cancer, also called colon cancer or large bowel cancer includes cancerous growths in the colon, rectum and appendix. With nearly 700,000 deaths worldwide per year, it is the fifth most common form of cancer in the United States and the third leading cause of cancer-related death in the Western world.

Invasive cancers that are confined within the wall of the colon (TNM stages I and II) are curable with surgery. If untreated, they spread to regional lymph nodes (stage III), where up to 73% are curable by surgery and chemotherapy. Cancer that metastasizes to distant sizes (stage IV) is usually not curable, although chemotherapy can extend survival, and in rare cases, surgery and chemotherapy together have seen patients through to a cure.

Colorectal cancer frequently presents with no symptoms. A genetic model of carcinogenesis has been developed, starting with adenomatous polyps that progress in a stepwise process to malignancy. Screening tests can detect colorectal polyps, some of which have the potential to become cancerous. Colonoscopy, an endoscopic examination of the entire colon, allows polyp detection and enables biopsy or the removal of the polyps during the procedure. Colorectal cancer diagnosis is established by histopathological examination of the tissue obtained from biopsy of the rumor.

The method of treatment for colorectal cancer depends on whether the cancer is in the colon or the rectum and on the stage of the disease. Staging occurs after colorectal cancer has been diagnosed and it evaluates the disease location and extent. Treatment may include surgery, chemotherapy, radiation therapy, or biological therapy; it may also include some combination of these treatments. Cancers of the colon are generally treated with surgery and chemotherapy. Patients whose cancer has spread beyond the colon to other parts of the body may be given palliative radiation therapy to control symptoms of metastatic disease. Cancers of the rectum are more prone to loco-regional recurrence, and radiation therapy and chemotherapy are given either before, during or after surgery.

GOAL OF THE GUIDELINE:

This guideline outlines several methods suitable for the employment of radiation therapy in conjunction with colon and rectal cancer treatment. These include the use of external radiation (three-dimensional conformal radiation therapy (3D-CRT), intra-operative radiation treatment (IORT), and rarely, internal radiation (brachytherapy). Advanced approaches such as intensity modulated radiation therapy (IJART) and/or image guided radiation therapy (IGRT) are not indicated as standard treatment for colorectal cancer. The radiation therapy (IGRT) are not indicated as standard treatment for colorectal cancer.

Proprietary

1-Colorectal Cancer

NIA Magellan.

Evidence-Based Clinical Guidelines for Radiation Oncology

- NIA Magellan Evidence-Based Clinical Guidelines are available on www.RadMD.com.
- Health plan medical directors review and approve all NIA Magellan clinical guidelines.



Step 3: Treatment plan review

	1.	-	
National Imaging	Associates, Inc.		

Original Date: March 2011
Page 1 of 7
Last Review Date: October 2014
Last Revised Date: June 2012
Implementation Date : October 2014

INTRODUCTION:

Colorectal cancer, also called colon cancer or large bowel cancer includes cancerous growths in the colon, rectum and appendix. With nearly 700,000 deaths worldwide per year, it is the fifth most common form of cancer in the United States and the third leading cause of cancer-related death in the Western world.

Invasive cancers that are confined within the wall of the colon (TNM stages I and II) are curable with surgery. If untreated, they spread to regional lymph nodes (stage III), where up to 73% are curable by surgery and chemotherapy. Cancer that metastasizes to distant sites (stage IV) is usually not curable, although chemotherapy an extend survival, and in rare cases, surgery and chemotherapy together have seen patients through to a cure.

Colorectal cancer frequently presents with no symptoms. A genetic model of carcinogenesis has been developed, starting with adenomatous polyps that progress in a stepwise process to malignancy. Screening tests can detect colorectal polyps, some of which have the potential to become cancerous. Colonoscopy, an endoscopic examination of the entire colon, allows polyp detection and enables biopsy or the removal of the polyps during the procedure. Colorectal cancer diagnosis is established by histopathological examination of the tissue obtained from biopsy of the tumor.

The method of treatment for colorectal cancer depends on whether the cancer is in the colon or the rectum and on the stage of the disease. Staging occurs after colorectal cancer has been diagnosed and it evaluates the disease location and extent. Treatment may include surgery, chemotherapy, radiation therapy, or biological therapy; it may also include some combination of these treatments. Cancers of the colon are generally treated with surgery and chemotherapy. Patients whose cancer has spread beyond the colon to other parts of the body may be given palliaitive radiation therapy to control symptoms of metastatic disease. Cancers of the rectum are more prone to loco-regional recurrence, and radiation therapy and chemotherapy are given either before, during or after surgery.

GOAL OF THE GUIDELINE:

This guideline outlines several methods suitable for the employment of radiation therapy in conjunction with colon and rectal cancer treatment. These include the use of external radiation (three-dimensional conformal radiation therapy (3D-CRT), intra-operative radiation treatment (IORT), and rarely, internal radiation (brachytherapy). Advanced approaches such as intensity modulated radiation therapy (IMRT) and/or image guided radiation therapy (IGRT) are not indicated as standard treatment for colorectal cancer. The radiation therapy (IGRT) are not indicated as standard treatment for colorectal cancer.

1-Colorectal Cancer Proprietary NIA Magellan.

Evidence-Based Clinical Guidelines for Radiation Oncology

- If NIA Magellan does not approve a treatment plan based on the information received, it is then reviewed by a radiation oncologist prior to rendering a denial.
- If NIA Magellan does not approve the treatment plan after the radiation oncologist's review, the oncologist will reach out to the requesting physician to review and discuss the treatment plan.



Step 3: Treatment plan review

Intake Level



Requests are evaluated using NIA Magellan's clinical algorithm

Requests can:

- 1. Approve
- 2. Require additional clinical review
- Pend for clinical validation of medical records

2 Initial Clinical Review

Nurses will review request and can:

- 1. Approve
- Send to NIA Magellan physician for additional clinical review



Physicians can:


- 1. Approve
- 2. Partially approve
- 3. Facilitate an ordering physician withdrawal



A peer-to-peer discussion is always available!



Step 3: Treatment plan review



Use the tracking number to check the status of the request



Step 3: Treatment plan review

Potential Outcomes

Treatment Plan Outcomes:

- Approved
- Partially Approved
- Denied

One authorization number encompasses all authorized procedures in a treatment plan.

NOTE: Only an NIA Magellan radiation oncologist can make a denial determination.





- Introduction
- Services and Treatments
- Authorization Process
- Notification of Determination
- Clinical Information
- Other Important Information
- Provider Tools
- Provider Relations Contact Information



- You will receive the treatment plan determination:
- Written and verbal provider notification (separate member notification)
- Approved requests include a list of authorized procedures
- Authorization detail also available on www.RadMD.com

REQU	Menu Logout He JEST VERIFICA nt Fax Coversheet	and the second se			
Patien	t Information				
Name: Date of Health F			Gender Membe		
Referri	ing Physician				
Name: Tax ID: Specialt Teatm	Brown MD, R yr Rediction Onc ent Facility		Phone: UPIN:		
Name: Tax ID: Case In	Brown Cancer	Center	Addres	1 Park Avenue Suite 500 Any City, Any State 631	
Reques Status: Validity	t ID: 9148B007 Approved	cer - 3D-Conformal Radiat Reques ICD9: - 05/22/2011		y with Brachytherapy, LDR Boost 02/01/2011 185	
3D Conf	ormal Radiation Therapy		Brachyt	herapy, LDR Boost	
	Treatment Deliveries - EBRT Treatment Management	Units 1 Billable Codes 1 7 25 Billable Codes 5 5 5	CPT4 77014 77328 77332 77331 77778	Procedure Category CT Guidance - Planning Brachytherapy Isodose Plan Treatment Devices Dosimetry Special Treatment Deliveries - Brachyther	Units 1 Billable Code 1 Billable Code 1 apy-LDR 1 Billable Code

Question	Answer
ase be advised that all data was current as of Thursday, May 01 2008 at 12:34 PM MST	



_									
N									
	Menu Log	out Help							
	_		_						
EXA	M REQUES	T VERIFICAT	ION: DET	AIL					
	Print Fax Covers	sheet							
Linio	ad Clinical Do	cument							
	ent Informa								
Nam		JOHN E DOE		Gender:	м				
Date	e: of Birth: th Plan:	2/15/1949 123456 Employe	e Health Plan	Member ID:		;600000			
Rend	dering Phys	ician							
Nam		TOM THOMAS, MI	D			123-4567			
Tax Spec	ialty:	12340000000 Radiation Oncolog	.v	UPIN:	MD12;	345			
Trea	tment Faci								
Nam	ei	CANCER TREATM	ENT CENTER	Address:	100.8	MAIN STREE	Τ		
Nam Tax I	e: ID:	CANCER TREATME	ENT CENTER	Address:		MAIN STREE OWN, USA 1:	-		
Nam Tax I	ei	CANCER TREATME	ENT CENTER	Address:			-		
Nam Tax I Case	e: ID: e Information:	CANCER TREATME 1234500000 DD Prostate Cancer - 1		ited Radiation The	ANYTO	OWN, USA 1:	-		
Nam Tax I Case	e: ID: • Information: • Description: • mest ID:	CANCER TREATME			ANYT(erapy (1 5/15/2)	OWN, USA 1:	-		
Nam Tax I Case Requ State Valid	e: ID: • Informatio • Description: • est ID: • : lity Dates:	CANCER TREATMI 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/2	Intensity Modula	ited Radiation Thi Request Date: Entry Nethod: ICD9:	ANYTO erapy (1 5/15/20 RadMD	OWN, USA 1: IMRT) 012	-		
Nam Tax I Case Requ State Valid	e: ID: Poscription: Nest ID: us:	CANCER TREATMI 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval	Intensity Modula	ited Radiation The Request Date: Entry Method:	ANYTO erapy (1 5/15/20 RadMD	OWN, USA 1:	-		
Nam Tax I Case Requ State Valid	e: ID: • Informatio • Description: • est ID: • : lity Dates:	CANCER TREATMI 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/2	Intensity Modula 2012	ited Radiation Thi Request Date: Entry Nethod: ICD9:	ANYTO erapy (1 5/15/20 RadMD	OWN, USA 1: IMRT) 012	-		
Nam Tax I Case Case Requ Stab Valid Plan	e: ID: Description: rest ID: us: lity Dates: ning Began: Date	CANCER TREATM 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/3 (not available)	Intensity Modula 2012 Proces	ited Radiation Thi Request Date: Entry Method: ICD9: Treatment Start lure Calegory	ANYT(5/15/2 RadMD 13 t: /21/	OWN, USA 1: (MRT) 012 2012 Approved	2345 Denied	E	Table Code:
Nam Tax 1 Case Requ State Valid Plan CPT4 77290 77334	e: ID: Description: rest ID: us: lity Dates: ning Began: Date 5/17/12 6:26A 5/17/12 6:26A	CANCER TREATME 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/: (not available) Phase M Initial Treatment M Initial Treatment	Intensity Modula 2012 Proces Simulation - Se Treatr	tted Radiation Thi Request Date: Entry Method: ICD9: Treatment Star Jure Calegory tup - Interm/Con nent Devices	ANYT(5/15/2 RadMD 13 t: /21/	OWN, USA 1: IMRT) 012 2012 Approved Units	Denled Units 0 0		
Nam Tax 1 Case Requ Stab Valid Plan CPT4 77290 77334 77014	e: ID: Description: nest ID: us: lity Dates: ning Began: Date 5/17/12 6:26A 5/17/12 6:26A	CANCER TREATMI 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/: (not available) Phase M Initial Treatment M Initial Treatment M Initial Treatment	Intensity Modula 2012 Procee Simulation - Se Treatr CT Guid	ted Radiation The Request Date: Entry Method: ICD9: Treatment Start dure Category tup - Interm/Con ment Devices ance - Planning	ANYTO srapy (1 5/15/20 RadMD 175 tt /21/	IMRT) 012 2012 Approved Units 1 2 1	Denied Units 0 0 0		
Nam Tax 1 Case Requ Stab Valid Plan CPT4 77290 77334 77014 77338	e: D: Description: pest ID: s: lity Dates: ning Began: Date 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A	CANCER TREATMI 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/2 (not available) Phase M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment	Intensity Modula 2012 Procee Simulation - Se Treatr CT Guid Treatment D	ted Radiation The Request Date: Entry Method: ICD9: Treatment Start ture Category tup - Interm/Con ment Devices ance - Planning evices - IMRT (MI	ANYTO srapy (1 5/15/20 RadMD 175 tt /21/	IMRT) 012 2012 Approved Units 1 2 1 1 1	Denied Units 0 0 0 0		
Nam Tax 1 Case Requ Stab Valid Plan CPT4 77290 77334 77014 77338 77301	e: D: e Informatic Description: rest ID: us: lity Dates: ning Began: Date 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A	CANCER TREATMI 1234500000 DN Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/1 (not available) Phase M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment	Intensity Modula 2012 Proceed Simulation - Se Treatr CT Guid Treatment D IMRT	ted Radiation The Request Date: Entry Method: ICD9: Treatment Starf dure Category tup - Interm/Con ment Devices ance - Planning evices - IMRT (MI Isodose Plan	ANYTO srapy (1 5/15/20 RadMD 175 tt /21/	IMRT) 012 2012 Approved Units 1 2 1 1 1 1	Denied Units 0 0 0 0		
Nam Tax 1 Case Requ State Valid Plan CPT4 77290 77334 77301 77338 77301	e: Description: rest ID: us: lity Dates: ning Began: Date 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A	CANCER TREATMI 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/1 (not available) Phase M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment	Intensity Modula 2012 Procee Simulation - Se Treatr CT Guid Treatment D IMRT Dosimet	ted Radiation Thi Request Date: Entry Method: ICD9: Treatment Start ture Category tup - Interm/Con ment Devices ance - Planning evices - IMRT (ML Isodose Plan ry - Calculation	ANYTO s/15/20 RadMD 10 t: /21/ np ex	OWN, USA 1: IMRT) 012 2012 Approved Units 1 2 1 1 1 1 1 1	Denied Units 0 0 0 0 0 0		
Nam Tax 1 Case Requ State Valid Plan CPT4 77290 77334 77014 77338 77301 77330 77300 77418	e: Description: mest ID: us: lity Dates: ning Began: 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A	CANCER TREATMI 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/1 (not available) Phase M Initial Treatment M Initial Treatment	Intensity Modula 2012 Procee Simulation - Se Treatr CT Guid Treatment De IMRT Dosimet Treatment De	ted Radiation Thi Request Date: Entry Method: ICD9: Treatment Start dure Category tup - Interm/Con nent Devices ance - Planning evices - IMRT (MI Isodose Plan ry - Calculation liveries - IMRT (M	ANYTO srapy (1 5/15/2) RadMD 1 tr /21/ np ex .c	IMRT) 012 2012 Approved Units 1 2 1 1 1 1	Denied Units 0 0 0 0		
Nam Tax 3 Case Requ state Valid Plan 77290 77334 77301 77301 77300 77301 77300 77301 77300 77301	e: D: Description: mest ID: us: lity Dates: ning Began: Date 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A	CANCER TREATMI 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/1 (not available) Phase M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment M Initial Treatment	Intensity Modula 2012 Simulation - Se Treatr CT Guid Treatment Do IMRT Dosimet Treatment De Treatment Mana	ted Radiation Thi Request Date: Entry Method: ICD9: Treatment Start dure Category tup - Interm/Con nent Devices ance - Planning evices - IMRT (MI Isodose Plan ry - Calculation liveries - IMRT (M	ANYTO erapy (I S/15/2/ RadMD 1 t: /21/ np ex .C	OWN, USA 1: IMRT) 012 2012 Approved Units 1 1 2 1 1 1 1 44	2345 Denied Units 0 0 0 0 0 0 0 0 1		
Nam Tax 1 Case Stati Valid Plan CPT4 77290 77334 77014 77338 77301 77301 77348 77418 77427 77336	e: D: Description: nest ID: us: lity Dates: ning Began: Date 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A	CANCER TREATMI 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/ (not available) Phase M Initial Treatment M Initial Treatment	Intensity Modula 2012 Simulation - Se Treatr CT Guid Treatment Do IMRT Dosimet Treatment De Treatment Mana Weekly Ph	ted Radiation The Request Date: Entry Method: ICD9: Treatment Starf Aure Category tup - Interm/Con ment Devices ance - Planning evices - IMRT (ML Isodose Plan ry - Calculation liveries - IMRT (M igement - 5 Treat	ANYTO erapy (I S/15/2/ RadMD 1 t: /21/ np ex .C	OWN, USA 1: IMRT) 012 2012 Approved Units 1 2 1 1 1 1 1 4 4 9	2345 Denied Units 0 0 0 0 0 0 0 0 1 0		
Nam Tax 1 Case Stati Valid Plan CPT4 77290 77334 77014 77338 77301 77301 77348 77418 77427 77336	e: ID: e Informatic Description: rest ID: us: lity Dates: ning Began: Date 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A 5/17/12 6:26A	CANCER TREATMI 1234500000 DD Prostate Cancer - 1 121368051 Partial Approval 5/15/2012-11/11/ (not available) Phase M Initial Treatment M Initial Treatment	Intensity Modula 2012 Proceed Simulation - See Treatment Do IMRT Dosimet Treatment De Irreatment Mana Weekly Ph CT Gu	ted Radiation The Request Date: Entry Method: ICD9: Treatment Start Aure Category tup - Interm/Con ment Devices ance - Planning evices - IMRT (ML Isodose Plan ry - Calculation liveries - IMRT (M gement - 5 Treat ysics Consultation	ANYTO srapy () S/15/20 RadMD 12 tr /21/ np ex .C	OWN, USA 1: (MRT) 012 2012 2012 1 1 2 1 1 1 1 1 4 4 4 9 9 9	2345 Denied Units 0 0 0 0 0 0 0 1 0 0 0 0		lable Code: lable Code:

Sample Authorization for Partial Approval



Approval Notification

Verbal notice and fax, letter mailed if fax fails.

Rendering – Can view approval on RadMD

Denial Notification

Verbal and written notice to ordering physician, written notice to member.

Authorization Validity Period

180 days from date of request for radiation oncology.

Appeal Instructions

NIA Magellan handles all firstlevel physician appeals.



Retrospective Review Process

 For Radiation Oncology - 14 calendar days from date of service, NIA Magellan will review request based on medical necessity.

Urgent/Expedited Authorization Process

 If an urgent clinical situation exists (outside of a hospital emergency room), please call NIA Magellan immediately. To get prior authorization, call 866-500-7664.





- Introduction
- Services and Treatments
- Authorization Process
- Notification of Determination
- Clinical Information
- Other Important Information
- Provider Tools
- Provider Relations Contact Information



NIGO DE CALLA National Imaging Associatas, he: D Base 07350 Premis, AZ 850857300 FACSIMILE TRANSMITTAL SHEET PLEASE FAX THIS FORM TO: 1-888-656-1321 Date:

ORDERING PHYSICIAN:			
FAX NUMBER:		TRACKING NUMBER:	
RE:	Authorization Request	MEMBER ID:	
PATIENT NAME:			
HEALTHPLAN:			
We have received your request f	for RADONC_PROC_DESC	. As we are unable to approv	e based on the information
provided to date, please respond	d to this fax as soon as possibl	e. Please limit your response	s to the most current
information related to this requ	est.		

Request for Further Clinical Information. We have received your request for RADONC_PROC_DESC. Please use this tool to assist us with the preauthorization process, by submitting by fax # 1-888-656-1321 or phone all relevant information requested below. For information regarding NIA clinical guidelines used for determinations, please see www.radmd.com CLINICAL GUIDELINES. To speak with an Initial Clinical Reviewer please call: 877-642-0522

THE FOLLOWING ADDITIONAL CLINICAL INFORMATION MAY BE NEEDED:

- 1. Clinical Rationale for Requested Therapy
- 2. TNM Staging
- 3. Margin status
- 4. Pathology Report

If additional clinical information is needed to complete an authorization request review:

- NIA Magellan will send a fax to the radiation oncologist detailing what clinical information it needs along with a fax coversheet.
- We stress the need to provide the clinical information as quickly as possible so NIA Magellan can make a determination.



National Imaging Associates, Inc. PD Bes 67300 Phomin, AZ 85082.7300

FACSIMILE TRANSMITTAL SHEET PLEASE FAX THIS FORM TO: 1-888-656-1321

Date:

ORDERING PHYSICIAN:			
FAX NUMBER:		TRACKINGNUMBER:	
RE:	Authorization Request	MEMBER ID:	
PATIENT NAME:			
HEALTH PLAN:			
We have received your request	for RADONC_PROC_DESC	2. As we are unable to approv	e based on the information
provided to date, please respon	d to this fax as soon as possib	le. Please limit your response	s to the most current
information related to this requ	est.		

Request for Further Clinical Information. We have received your request for RADONC_PROC_DESC. Please use this tool to assist us with the preauthorization process, by submitting by fax # 1-888-656-1321 or phone all relevant information requested below. For information regarding NIA clinical guidelines used for determinations, please see www.radmd.com CLINICAL GUIDELINES. To speak with an Initial Clinical Reviewer please call: 877-642-0522


THE FOLLOWING ADDITIONAL CLINICAL INFORMATION MAY BE NEEDED:

- 1. Clinical Rationale for Requested Therapy
- 2. TNM Staging
- 3. Margin status
- 4. Pathology Report

- The timeframe for rendering a determination begins after receipt of clinical information.
- Provide clinical information as soon as possible to ensure timely processing of request.



- Two ways to submit clinical information to NIA Magellan:
- 1. RadMD Upload
 - Upload clinical documentation electronically
- 2. Fax
 - Use the fax cover sheet when faxing clinical information to NIA Magellan.



Be sure to use the NIA Magellan fax cover sheet for all transmissions of clinical information!



You can print additional copies of fax cover sheets from RadMD or request them via the Call Center at 888-642-7649.



Be sure to use the NIA Magellan fax cover sheet for all transmissions of clinical information!





Change or add additional services for an approved treatment plan

Authorizations

• Call all modifications of approved treatment plan requests into the Call Center.

- NIA Magellan will review modifications for medical necessity.
- Be prepared to supply additional clinical information if necessary.
- NIA Magellan will make a determination after it receives all requested information.
- Authorization number will NOT change





- Introduction
- Services and Treatments
- Authorization Process
- Notification of Determination
- Clinical Information
- Other Important Information
- Provider Tools
- Provider Relations Contact Information



Other Important Information

- You cannot initiate authorizations via fax.
- Submit additional clinical information via fax or RadMD upload after you have initiated a request.
- You do not need a cover sheet to upload records on RadMD.
- Provide any clinical information as quickly as possible so NIA Magellan can make a determination.
- The timeframe for rendering a determination begins after receipt of clinical information.



Other Important Information

Proton Beam Therap

reatment Pla

Transition Cases

Complete the Radiation Therapy Treatment Notification Form and fax to BlueCross at 803-264-0258

- Complete this form to notify BlueCross about radiation treatment for members who started treatment prior to January 1, 2015.
- Form is available at www.RadMD.com, www.SouthCarolinaBlues.com and www.BlueChoiceSC.com
- We do not require a medical necessity review for these patients.

BueCross BlueShield of South Carolina and LeChoice HealthPlan of South Carolina



Therapy Treatment Notification Form for Transition Cases

	erapy Treatment Notification Form to notify BlueCross treatment impacted by one of these scenarios (select		na or BlueChoice			
	n therapy prior to the program start of January 1, 2015					
Patient began radiatio	n therapy prior to coverage by BlueCross or BlueChoic	e®				
Patient began radiation	n therapy while in an inpatient setting and treatment i	s expected to continue on a	an outpatient basis			
	 Providers can send completed forms for each patien A confirmation notification will be faxed to the providence 					
bmitted By	Name (Last, First):					
te	Phone:	Fax	*Required			
ember	Name (Last, First):					
formation	Address:					
	Gender: C M C F DOB:	Member ID:				
ovider	Radiation Oncologist's Name:					
formation	Address:					
	Phone:	Fax				
	Physician Tax ID:					
	Radiation Therapy Facility:					
	Address:					
	Phone:	Fax				
	Facility Tax ID:					
diation Therapy eatment Plan	Diagnosis – ICD:					
formation	Primary Tumor Site Breast Color Being Treated Lung Other		Rectal			
	Treatment Start Date:	Treatment End Date:				
	Radiation Therapy Type	CPT code	# of Treatments			
	Low-dose-rate (LDR) Brachytherapy					
	High-dose-rate (HDR) Brachytherapy					
	2D Conventional Radiation Therapy (2D)					
	3D Conformal Radiation Therapy (3D-CRT)					
	Intensity Modulated Radiation Therapy (IMRT)					

ubmit a new treatment notification form if there is a change to CPT codes, # of treatments and/o

Check here if this form is to report changes to a previously submitted form

NIA Magellan does not require a medical necessity review for radiation therapy that started prior to January 1, 2015.



Provider Networks

NIA Magellan will use the existing BlueCross and BlueChoice network of radiation oncologists and cancer treatment facilities as its preferred providers for delivering radiation oncology solutions to BlueCross and BlueChoice members throughout South Carolina.



Other Important Information

Claims Process

Claim Submission

Appeal Process

- Radiation oncologists and cancer treatment centers should continue to submit claims to BlueCross and BlueChoice
 Providers are strongly encouraged to file claims using EMC (Electronic Media Claims)
 Providers can also submit claims online using My Insurance ManagerSM available at www.SouthCarolinaBlues.com or www.BlueChoiceSC.com
 - Providers can also check claim status through My Insurance Manager.

 In the event of a prior authorization or claims payment denial, providers can appeal the decision through BlueCross.

 Physicians should follow the instructions on their nonauthorization letters or remittance notifications.





- Introduction
- Services and Treatments
- Authorization Process
- Notification of Determination
- Clinical Information
- Other Important Information
- Provider Tools
- Provider Relations Contact Information



Provider Tools



RadMD Website

- Available 24/7
- Ordering physicians can request authorization and view authorization status
- Upload additional clinical information
- Access NIA Magellan resources
 - List of CPT procedure codes requiring preauthorization
 - o Cancer site checklists
 - o Evidence-based clinical guidelines (by diagnosis)
 - Outpatient Radiation Therapy Billable CPT[®]
 Codes Claim Resolution Matrix
 - Radiation Oncology Utilization Quick Reference
 Guide 40



Provider Tools



Interactive Voice Response (IVR) System

- Toll-free authorization and information number, 866-500-7664
- Monday through Friday, 8 a.m. to 8 p.m.
- Saturday 8 a.m. to 1 p.m. EST



www.RadMD.com

IMPORTANT: We require everyone in your organization to have his or her own separate username and password due to HIPAA regulations.

Steps for radiation oncologists:

- 1. Click the "New User" button on the right side of the home page.
- 2. Select "Physician's office that prescribes radiation oncology procedures."
- 3. Fill out the application and select "Submit."
 - You must include your email address in order for the webmaster to respond to you with your NIA Magellanapproved username and password.
 - NOTE: On subsequent visits to the site, select "Sign In" to proceed.

Provider Tools

RadMD Sign In 24/7 online access for imaging facilities and health plans to NIA's RadMD Web site. Sign In New User	
Track an Authorization Authorization Tracking Number G0	
Which of the following best describes your company?	
Physicians office that prescribes radiation oncology proced	ures 👻
Please Select an Appropriate Description Imaging Facility or Hospital that performs radiology exams Health Insurance company Physician's office that orders radiology exams Cancer Treatment Facility or Hospital that performs radiatio	
Physicians office that prescribes radiation oncology proced	ures
NA	

1

2

3

RADMD.COM: APPLIC	for yourself. Shared a	
In order for your account to be art	ivated, you must be able	occounts are not allowed.
	r to ensure that emails f	to receive emails from RadMDSupport@magellanhea rom RadMDSupport@magellanhealth.com can be rece
Which of the following best describe - Please Select an Appropriate D		2
- Prease Select an Appropriate L		-
Choose a User ID	alon -	
5-20 Charadala		
Name		
First	Last	
Phone	Fax	
(mm) 2000-20000	(hter) mor soon	
Company Name	JOB TIEM	
Inal	Confirm Ernall	
exemple: you@company.com		
ferrides bedre bedre		
Address		
example: 123 Main St.	example: 133 Main St.	
example: Suite A (optional)		
100	14M) 🗶 2	la l
Your Superior		
The manager or supervisor respo This cannot be yourself.	naible for terminating yo	ur access.
First	Last	
	Email	
Phone	a. magent	
Phone (Jour) sum-sumps	example: beasprom	winy dom.



www.RadMD.com

IMPORTANT: Designate an "administrator" for the facility who manages the access for the entire facility.

Steps for cancer treatment facilities:

- 1. Click the "New User" button on the right side of the home page.
- 2. Select "Cancer Treatment Facility or Hospital that performs radiation oncology procedures."
- 3. Fill out the application and select "Submit."
 - You must include your email address in order for the webmaster to respond to you with your NIA Magellanapproved username and password.

NOTE: On subsequent visits to the site, select "Sign In" to proceed.

Provider Tools

)	RadMD Sign In 24/7 online access for imaging facili health plans to NIA's RadMD Web sit Sign In New User Track an Authorization Authorization Tracking Number	ties and te. Go				
	Which of the following best describes your company?					
	Cancer Treatment Facility or Hospital that performs radiation oncology procedures 🔻					
	Please Select an Appropriate Description Imaging Facility or Hospital that performs radiology e Health Insurance company Physician's office that orders radiology exams Cancer Treatment Facility or Hospital that performs Physicians office that prescribes radiation oncology	radiation oncolog	ay procedures			

1

2

3	Login RadMD Home R & 0 M D . C 0 M : A P	NOT NOT A NEW ACC	0 U N T
<u> </u>	In order for your account b	inistrator to ensure that emails from RadM	are not allowed. emails from RadNDSupport@magellanheath.com. Please DSupport@magellanhealth.com can be received.
	- Please Select an Appro	opriate Description	*
	What about read-only rad-	ology offices	
	Choose a User ID		
	5-20 Charadara		
	Name		
	First	Last	
	Phone	Fee	
	20000 2000 2000 2000 C	(3000) 3000 30000	
	Company Name	Job Title	
	Email	Confirm Email	
	exemple: you@company	A 6071	
	Address		
	example: 123 Main St.		
	example: Suite A (option	(State) 210	
	Your Superior	Donal 20 (10	
	Tour Superior		
	The manager or supervise This cannot be yourself.	or responsible for terminating your access.	
	Rama		
	Feat	Last	
	Phone	Email	



Agenda

- Introduction
- Services and Treatments
- Authorization Process
- Notification of Determination
- Clinical Information
- Other Important Information
- Provider Tools
- **Provider Relations Contact Information**



NIA Magellan Dedicated Provider Relations Manager

- Name: Anthony (Tony) Salvati
- Phone: 800-450-7281, ext. 75537
- Email: <u>alsalvati@magellanhealth.com</u>

Tony is the liaison between BlueCross Provider Relations and NIA Magellan.

BlueCross and BlueChoice Provider Relations and Education

- Phone: 803-264-4730
- Email: <u>Provider.Education@bcbssc.com</u>

Providing educational tools to radiation oncologists and treatment facilities on processes and procedures.